Oncomine Dx Target Test
Life Technologies Corporation · Decision date Aug 8, 2025
What did the FDA approve?
FDA records P160045/S049 as a supplement to PMA P160045, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 8, 2025.
FDA approval order statement
Approval to include a companion diagnostic indication to identify patients with non-small cell lung cancer (NSCLC) harboring ERBB2/HER2 activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions) who are eligible for treatment with HERNEXEOS (zongertinib).
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Aug 8, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P160045/S049
- Regulatory pathway
- PMA supplement
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Aug 8, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P160045/S049 received
Application receipt date recorded by FDA.
P160045/S049 · FDA decision
Normal 180 Day Track
P160045/S050 · Related supplement
Oncomine Dx Target Test
P160045/S051 · Related supplement
Oncomine Dx Target Test
P160045/S052 · Related supplement
Oncomine Dx Target Test
Timeline entries are records held by MedtechLedger for P160045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Target TestP160045/S050 | Life Technologies Corporation | PMA supplement | Nov 19, 2025 | FDA |
Oncomine Dx Target TestP160045/S051 | Life Technologies Corporation | PMA supplement | Nov 21, 2025 | FDA |
Oncomine Dx Target TestP160045/S052 | Life Technologies Corporation | PMA supplement | Mar 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Life Technologies Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5781 Van Allen Way, Carlsbad, CA, 92008
Sources and methodology
- Original FDA record: P160045/S049
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



